Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 04, 2021

SELL
$5.98 - $7.51 $3.4 Million - $4.27 Million
-568,433 Closed
0 $0
Q1 2021

May 04, 2021

SELL
$6.98 - $11.29 $2.25 Million - $3.63 Million
-321,906 Reduced 36.16%
568,433 $4.16 Million
Q1 2020

May 12, 2020

BUY
$3.51 - $6.17 $1.76 Million - $3.09 Million
500,425 Added 128.34%
890,339 $4.03 Million
Q3 2018

Nov 08, 2018

SELL
$6.0 - $11.35 $37,320 - $70,597
-6,220 Reduced 1.57%
389,914 $3.44 Million
Q2 2018

Aug 01, 2018

SELL
$4.82 - $8.53 $5,735 - $10,150
-1,190 Reduced 0.3%
396,134 $3.38 Million
Q4 2017

Feb 06, 2018

SELL
$4.58 - $10.81 $393 - $929
-86 Reduced 0.02%
397,324 $2.04 Million
Q3 2017

Nov 06, 2017

SELL
$8.25 - $10.81 $4,207 - $5,513
-510 Reduced 0.13%
397,410 $4.3 Million
Q2 2017

Aug 15, 2017

BUY
N/A
397,920
397,920 $3.43 Million

Others Institutions Holding RDHL

About RedHill Biopharma Ltd.


  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $465M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track This Portfolio

Track Migdal Insurance & Financial Holdings Ltd. Portfolio

Follow Migdal Insurance & Financial Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.